Cargando…
Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
In patients with early-stage endocrine receptor-positive (ER+) breast cancer (BC), adjuvant endocrine therapy (ET) for 5 years is the standard of care. However, for some patients, the risk of recurrence remain high for up to 15 years after diagnosis and extended ET beyond 5 years may be a reasonable...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656848/ https://www.ncbi.nlm.nih.gov/pubmed/36362392 http://dx.doi.org/10.3390/ijms232113604 |
_version_ | 1784829540919410688 |
---|---|
author | Saponaro, Mariarosaria Annunziata, Luigi Turla, Antonella Viganò, Ilaria De Laurentiis, Michele Giuliano, Mario Del Mastro, Lucia Montemurro, Filippo Puglisi, Fabio De Angelis, Carmine Buono, Giuseppe Schettini, Francesco Arpino, Grazia |
author_facet | Saponaro, Mariarosaria Annunziata, Luigi Turla, Antonella Viganò, Ilaria De Laurentiis, Michele Giuliano, Mario Del Mastro, Lucia Montemurro, Filippo Puglisi, Fabio De Angelis, Carmine Buono, Giuseppe Schettini, Francesco Arpino, Grazia |
author_sort | Saponaro, Mariarosaria |
collection | PubMed |
description | In patients with early-stage endocrine receptor-positive (ER+) breast cancer (BC), adjuvant endocrine therapy (ET) for 5 years is the standard of care. However, for some patients, the risk of recurrence remain high for up to 15 years after diagnosis and extended ET beyond 5 years may be a reasonable option. Nevertheless, this strategy significantly increases the occurrence of side effects. Here we summarize the available evidence from randomized clinical trials on the efficacy and safety profile of extended ET and discuss available clinical and genomic tools helpful to select eligible patients in daily clinical practice. |
format | Online Article Text |
id | pubmed-9656848 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96568482022-11-15 Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests Saponaro, Mariarosaria Annunziata, Luigi Turla, Antonella Viganò, Ilaria De Laurentiis, Michele Giuliano, Mario Del Mastro, Lucia Montemurro, Filippo Puglisi, Fabio De Angelis, Carmine Buono, Giuseppe Schettini, Francesco Arpino, Grazia Int J Mol Sci Review In patients with early-stage endocrine receptor-positive (ER+) breast cancer (BC), adjuvant endocrine therapy (ET) for 5 years is the standard of care. However, for some patients, the risk of recurrence remain high for up to 15 years after diagnosis and extended ET beyond 5 years may be a reasonable option. Nevertheless, this strategy significantly increases the occurrence of side effects. Here we summarize the available evidence from randomized clinical trials on the efficacy and safety profile of extended ET and discuss available clinical and genomic tools helpful to select eligible patients in daily clinical practice. MDPI 2022-11-06 /pmc/articles/PMC9656848/ /pubmed/36362392 http://dx.doi.org/10.3390/ijms232113604 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Saponaro, Mariarosaria Annunziata, Luigi Turla, Antonella Viganò, Ilaria De Laurentiis, Michele Giuliano, Mario Del Mastro, Lucia Montemurro, Filippo Puglisi, Fabio De Angelis, Carmine Buono, Giuseppe Schettini, Francesco Arpino, Grazia Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests |
title | Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests |
title_full | Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests |
title_fullStr | Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests |
title_full_unstemmed | Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests |
title_short | Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests |
title_sort | extended adjuvant endocrine treatment in luminal breast cancers in the era of genomic tests |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656848/ https://www.ncbi.nlm.nih.gov/pubmed/36362392 http://dx.doi.org/10.3390/ijms232113604 |
work_keys_str_mv | AT saponaromariarosaria extendedadjuvantendocrinetreatmentinluminalbreastcancersintheeraofgenomictests AT annunziataluigi extendedadjuvantendocrinetreatmentinluminalbreastcancersintheeraofgenomictests AT turlaantonella extendedadjuvantendocrinetreatmentinluminalbreastcancersintheeraofgenomictests AT viganoilaria extendedadjuvantendocrinetreatmentinluminalbreastcancersintheeraofgenomictests AT delaurentiismichele extendedadjuvantendocrinetreatmentinluminalbreastcancersintheeraofgenomictests AT giulianomario extendedadjuvantendocrinetreatmentinluminalbreastcancersintheeraofgenomictests AT delmastrolucia extendedadjuvantendocrinetreatmentinluminalbreastcancersintheeraofgenomictests AT montemurrofilippo extendedadjuvantendocrinetreatmentinluminalbreastcancersintheeraofgenomictests AT puglisifabio extendedadjuvantendocrinetreatmentinluminalbreastcancersintheeraofgenomictests AT deangeliscarmine extendedadjuvantendocrinetreatmentinluminalbreastcancersintheeraofgenomictests AT buonogiuseppe extendedadjuvantendocrinetreatmentinluminalbreastcancersintheeraofgenomictests AT schettinifrancesco extendedadjuvantendocrinetreatmentinluminalbreastcancersintheeraofgenomictests AT arpinograzia extendedadjuvantendocrinetreatmentinluminalbreastcancersintheeraofgenomictests |